Price movement over the last 24 hours
Alcon AG vs Tenet Healthcare Corporation — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Tenet Healthcare Corporation trades at $206.47 (market cap $17.76B). The key difference: Alcon AG is the larger of the two by market cap, and Alcon AG pays a 0.54% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| ALC | THC | |
|---|---|---|
Market Cap | $32.69B | $17.76B |
Sector | Health | Health |
52-Week High | $92.22 | $244.80 |
52-Week Low | $62.02 | $148.38 |
Enterprise Value | $36.28B | $28.00B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Tenet Healthcare (THC) trades at $206.19, up 1.21% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The stock shows robust fundamentals with a P/E of 10.72, net income margin of 7.79%, and consistent earnings beats in recent quarters. Recent news highlights growth in outpatient care and positive market performance amid broader dips.
Outlook remains positive with an 81.25% analyst buy rating and $233.38 consensus price target, though overbought RSI signals near-term caution. Risks include healthcare regulatory pressures and debt levels, but expanding admissions and solid cash flow support long-term upside for value and growth investors.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →